Alaproclate

Alaproclate (GEA-654) is a psychoactive drug and research chemical that was being developed as an antidepressant by the Swedish pharmaceutical company Astra AB (now AstraZeneca) in the 1970s. It acts as a selective serotonin reuptake inhibitor (SSRI), and along with zimelidine and indalpine, was one of the first of its kind. Development was discontinued due to the observation of liver complications in rodent studies. Some studies have found that it acts as a noncompetitive NMDA antagonist, but does not have discriminative stimulus properties similar to phencyclidine.